In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...
Read More
In a nutshell This study evaluated the optimal treatment regimens given before and after surgery in terms of improving the survival outcomes in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC). The data showed that chemotherapy plus trastuzumab (Herceptin) and pertuzumab (Perjeta) was the best treatment...
Read More
In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...
Read More
In a nutshell The study compared the effectiveness and safety of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) combined therapy with nab-paclitaxel alone in patients with triple-negative breast cancer (TNBC). The study found that combined therapy was more effective than single therapy but it had more serious side effects in these...
Read More
In a nutshell The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients. Some background There are many...
Read More
In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...
Read More
In a nutshell This study evaluated the safety profile of palbociclib (Ibrance) combined with either fulvestrant (Faslodex) or letrozole (Femara) in patients with hormone-receptor-positive (HR+) and HER2 negative (HER2 -) advanced breast cancer (BC). The data showed that both palbociclib regimens were safe and tolerated in these patients with some...
Read More
In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...
Read More
In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...
Read More
In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...
Read More
In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...
Read More
In a nutshell This study aimed to investigate the safety and risk of disease recurrence in breast cancer survivors who were treated with systemic (whole-body) hormone replacement therapy (HRT). This study concluded that use of HRT increased the risk of disease recurrence in these patients. Some background Some breast...
Read More
